The last 2 decades have witnessed a revolution in acute reperfusion therapy for ST-segment elevation myocardial infarction (STEMI). This therapy has focused on patients who present within the first 12 hours of infarction, in the belief that the benefit of therapy is minimal after that time. However, a significant minority of patients present with STEMI more than 12 hours after the onset of chest pain. In 2 large registry studies,1- 2 patients presenting after 12 hours represented 8.5% and 31.3% of all patients with STEMI. Available randomized trial evidence has until now suggested little role for acute reperfusion therapy in this setting. The Fibrinolytic Therapy Trialist Collaboration3 reported that mortality was not reduced by thrombolytic therapy in patients presenting after 12 hours. Based on these data, existing clinical practice guidelines4- 5 strongly favor the use of acute reperfusion therapy in patients presenting within 12 hours but are more cautious about the potential value of reperfusion therapy in patients presenting later than 12 hours. However, the lack of benefit may, in part, be due to the inability of thrombolytic drugs to restore patency in vessels that have been occluded for several hours.6
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature
Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal
Instructions
Thank you for submitting a comment on this article. It will be reviewed by JAMA editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest* Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 2
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Register Now
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Need assistance?
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.